Highlights on two decades with microbiota and inflammatory bowel disease from etiology to therapy

Hussein, Inaya Hajj; Dosh, Laura; Qassab, Mohamad Al; Jurjus, Rosalyn A.; Masri, Jad El; Nader, Celine Abi; Rappa, Francesca; Leone, Angelo; Jurjus, A

doi:10.1016/j.trim.2023.101835

Cited by 6 publications

(7 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of IBD (Fig. 3 ), the literature about the pathogenetic role of microbiota alterations is rich and consolidated, and therapeutic approaches based on this relationship have been already proposed (see the recent reviews [ 108 – 111 ]). Much less is known on the possible influence of ASNP on the development of IBD.…”

Section: Potential Roles In Pathology and Consequences Of Exposure Of...mentioning

confidence: 99%

Amorphous silica nanoparticles and the human gut microbiota: a relationship with multiple implications

Bianchi,

Chiu,

Taurino

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Amorphous silica nanoparticles (ASNP) are among the nanomaterials that are produced in large quantities. ASNP have been present for a long time in several fast-moving consumer products, several of which imply exposure of the gastrointestinal tract, such as toothpastes, food additives, drug excipients, and carriers. Consolidated use and experimental evidence have consistently pointed to the very low acute toxicity and limited absorption of ASNP. However, slow absorption implies prolonged exposure of the intestinal epithelium to ASNP, with documented effects on intestinal permeability and immune gut homeostasis. These effects could explain the hepatic toxicity observed after oral administration of ASNP in animals. More recently, the role of microbiota in these and other ASNP effects has attracted increasing interest in parallel with the recognition of the role of microbiota in a variety of conditions. Although evidence for nanomaterial effects on microbiota is particularly abundant for materials endowed with bactericidal activities, a growing body of recent experimental data indicates that ASNPs also modify microbiota. The implications of these effects are recounted in this contribution, along with a discussion of the more important open issues and recommendations for future research. Graphical Abstract

show abstract

Section: Potential Roles In Pathology and Consequences Of Exposure Of...mentioning

confidence: 99%

Amorphous silica nanoparticles and the human gut microbiota: a relationship with multiple implications

Bianchi,

Chiu,

Taurino

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Their etiology is still not fully understood; however, aberrations in the secretion of cytokines such as interferon-𝛾, IL-5, IL-1β, IL-6, and TNF-α are undoubtedly involved in the pathogenesis of IBD. These proinflammatory cytokines were recognized to activate NFκB and MAPK, resulting in proinflammatory effects responsible for intestinal tissue pathology, including mucosal barrier disfunction and bacterial dysbiosis, as well as extra-intestinal comorbidities such as inflammation-induced bone loss [45,46,[48][49][50].…”

Section: Irisin and Inflammatory Bowel Diseasementioning

confidence: 99%

The Role of the Myokine Irisin in the Protection and Carcinogenesis of the Gastrointestinal Tract

Pinkas,

Brzozowski

2024

Antioxidants

View full text Add to dashboard Cite

Recently discovered irisin, a member of the myokines family, is a potential mediator of exercise-induced energy metabolism and a factor promoting browning of the white adipose tissue. Recent evidence indicates that this myokine, released from contracting muscles, can mediate the beneficial effects of exercise on health. Irisin may be a potential therapeutic agent against obesity and has been shown to play an important role in the protection of various cells, tissues, and organs due to its anti-inflammatory, antioxidative, and anti-cancer properties. Our aim was to review the recent experimental and clinical studies on irisin and its expression, release into the bloodstream, tissue targets, and potential contribution to the protective effects of exercise in the gastrointestinal tract. Particular emphasis was placed on inflammatory bowel disease, intestinal ischemia/reperfusion injury, periodontitis, and other digestive tract disorders, including carcinogenesis. Overall, irisin holds significant potential as a novel target molecule, offering a safe and therapeutic approach to treating various gastrointestinal diseases.

show abstract

“…This condition can be classified into two different categories, defined as ulcerative colitis (superficial inflammation appears on the colon) and Crohn's disease (transmural inflammation can occur along the whole gastrointestinal tract). Although the trigger of inflammation is unknown, in subjects with genetic susceptibility, inflammation may be due to exacerbated immune responses to gut microbiota antigens under certain environmental conditions [66]. The release of proinflammatory mediators and chronic inflammation has been associated with an increase in noxious bacteria, such as Proteobacteria (e.g., Escherichia coli).…”

Section: Immunomodulatory Conditions Inflammatory Bowel Disease (Ibd)mentioning

confidence: 99%

NAD+ Precursors and Intestinal Inflammation: Therapeutic Insights Involving Gut Microbiota

Niño-Narvión,

Rojo-López,

Martinez-Santos

et al. 2023

Nutrients

View full text Add to dashboard Cite

The oxidized form of nicotinamide adenine dinucleotide (NAD+) is a critical metabolite for living cells. NAD+ may act either as a cofactor for many cellular reactions as well as a coenzyme for different NAD+-consuming enzymes involved in the physiological homeostasis of different organs and systems. In mammals, NAD+ is synthesized from either tryptophan or other vitamin B3 intermediates that act as NAD+ precursors. Recent research suggests that NAD+ precursors play a crucial role in maintaining the integrity of the gut barrier. Indeed, its deficiency has been associated with enhanced gut inflammation and leakage, and dysbiosis. Conversely, NAD+-increasing therapies may confer protection against intestinal inflammation in experimental conditions and human patients, with accumulating evidence indicating that such favorable effects could be, at least in part, mediated by concomitant changes in the composition of intestinal microbiota. However, the mechanisms by which NAD+-based treatments affect the microbiota are still poorly understood. In this context, we have focused specifically on the impact of NAD+ deficiency on intestinal inflammation and dysbiosis in animal and human models. We have further explored the relationship between NAD+ and improved host intestinal metabolism and immunity and the composition of microbiota in vivo. Overall, this comprehensive review aims to provide a new perspective on the effect of NAD+-increasing strategies on host intestinal physiology.

show abstract

Highlights on two decades with microbiota and inflammatory bowel disease from etiology to therapy

Cited by 6 publications

References 103 publications

Amorphous silica nanoparticles and the human gut microbiota: a relationship with multiple implications

Amorphous silica nanoparticles and the human gut microbiota: a relationship with multiple implications

The Role of the Myokine Irisin in the Protection and Carcinogenesis of the Gastrointestinal Tract

NAD+ Precursors and Intestinal Inflammation: Therapeutic Insights Involving Gut Microbiota

Contact Info

Product

Resources

About